297 related articles for article (PubMed ID: 32479105)
1. Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer.
Zawaideh JP; Sala E; Pantelidou M; Shaida N; Koo B; Caglic I; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
Br J Radiol; 2020 Aug; 93(1112):20200298. PubMed ID: 32479105
[TBL] [Abstract][Full Text] [Related]
2. Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer.
Khoo CC; Eldred-Evans D; Peters M; Bertoncelli Tanaka M; Noureldin M; Miah S; Shah T; Connor MJ; Reddy D; Clark M; Lakhani A; Rockall A; Hosking-Jervis F; Cullen E; Arya M; Hrouda D; Qazi H; Winkler M; Tam H; Ahmed HU
BJU Int; 2020 Jan; 125(1):49-55. PubMed ID: 31599113
[TBL] [Abstract][Full Text] [Related]
3. Making an art into a science: a mathematical "Likert tool" can change PI-RADS (v2) scores into Likert scores when reporting multiparametric MRI for prostate cancer.
Stevens WM; Parchment-Smith C; Melling PP; Smith JT
Acta Radiol; 2023 Mar; 64(3):1245-1254. PubMed ID: 35815700
[TBL] [Abstract][Full Text] [Related]
4. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
5. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
Singh S; Rogers H; Kanber B; Clemente J; Pye H; Johnston EW; Parry T; Grey A; Dinneen E; Shaw G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Giganti F; Atkinson D; Moore CM; Whitaker HC; Alexander DC; Panagiotaki E; Punwani S
Radiology; 2022 Dec; 305(3):623-630. PubMed ID: 35916679
[TBL] [Abstract][Full Text] [Related]
6. Is Likert better than PI-RADS at predicting prostate cancer on MRI and can a mathematical algorithm achieve similar results?
Stevens W; Parchment-Smith C; Adiotomre E; Hulson O; Khan A; Melling P; Pierre S; Smith J
Acta Radiol; 2023 Sep; 64(9):2659-2666. PubMed ID: 37438925
[TBL] [Abstract][Full Text] [Related]
7. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
8. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
9. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
10. Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems.
Sokhi HK; Wilson A; Pindoria N; McNamara C; Padhani AR; Meer Z; Pope A
Clin Radiol; 2022 Jul; 77(7):541-547. PubMed ID: 35570157
[TBL] [Abstract][Full Text] [Related]
11. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
[TBL] [Abstract][Full Text] [Related]
12. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
[TBL] [Abstract][Full Text] [Related]
13. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Mazzone E; Stabile A; Pellegrino F; Basile G; Cignoli D; Cirulli GO; Sorce G; Barletta F; Scuderi S; Bravi CA; Cucchiara V; Fossati N; Gandaglia G; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Oct; 4(5):697-713. PubMed ID: 33358543
[TBL] [Abstract][Full Text] [Related]
14. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
15. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
[No Abstract] [Full Text] [Related]
17. Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies.
Rastinehad AR; Waingankar N; Turkbey B; Yaskiv O; Sonstegard AM; Fakhoury M; Olsson CA; Siegel DN; Choyke PL; Ben-Levi E; Villani R
PLoS One; 2015; 10(11):e0143404. PubMed ID: 26605548
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
19. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
[TBL] [Abstract][Full Text] [Related]
20. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
